Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IPO Failures Can Set Up Biotech Successes

This article was originally published in Start Up

Executive Summary

Did the 31 biotechs who pulled IPOs since 2003 destroy value? By and large, no-thanks to a growing variety of financing and exit options, most thanks to Pharma's increasing appetite for high-value deals and deeper private equity pockets.

Related Content

Can a Hippo Save the IPO Market for Life Sciences?
NovaCardia & Domain: New-Model Spec Pharma Investing
Biotech IPOs: Why Values Will Increase
European IPOs Hold Their Own
The Price is Wrong: Finding Alternatives to Traditional IPOs
Infinity Reverse Merges Into Discovery Partners
Trade Sales Trump IPOs, Even for Platforms
Stepping Out, Not Up: Better Returns for VCs Through M&A?
Theravance: Having Cake and Eating It
Speedel Group: Strings Attached? No Problem


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts